Novozymes Past Earnings Performance
Past criteria checks 3/6
Novozymes has been growing earnings at an average annual rate of 1.5%, while the Chemicals industry saw earnings growing at 17.1% annually. Revenues have been growing at an average rate of 5.4% per year. Novozymes's return on equity is 21.2%, and it has net margins of 16.9%.
Key information
1.5%
Earnings growth rate
2.5%
EPS growth rate
Chemicals Industry Growth | 13.1% |
Revenue growth rate | 5.4% |
Return on equity | 21.2% |
Net Margin | 16.9% |
Next Earnings Update | 03 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Novozymes makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 17,899 | 3,024 | 3,325 | 2,017 |
30 Sep 23 | 17,825 | 3,209 | 3,291 | 2,013 |
30 Jun 23 | 17,736 | 3,425 | 3,319 | 2,027 |
31 Mar 23 | 17,805 | 3,628 | 3,284 | 2,010 |
31 Dec 22 | 17,553 | 3,676 | 3,198 | 1,986 |
30 Sep 22 | 16,858 | 3,418 | 3,292 | 1,951 |
30 Jun 22 | 16,252 | 3,108 | 3,108 | 1,911 |
31 Mar 22 | 15,546 | 3,093 | 2,995 | 1,912 |
31 Dec 21 | 14,951 | 3,146 | 2,828 | 1,982 |
30 Sep 21 | 14,563 | 3,175 | 2,492 | 1,995 |
30 Jun 21 | 14,233 | 3,044 | 2,397 | 2,037 |
31 Mar 21 | 14,002 | 2,895 | 2,308 | 2,008 |
31 Dec 20 | 14,012 | 2,825 | 2,299 | 1,905 |
30 Sep 20 | 14,297 | 3,093 | 2,303 | 1,850 |
30 Jun 20 | 14,570 | 3,020 | 2,431 | 1,893 |
31 Mar 20 | 14,679 | 3,273 | 2,497 | 1,968 |
31 Dec 19 | 14,374 | 3,154 | 2,459 | 1,966 |
30 Sep 19 | 14,357 | 3,069 | 2,492 | 1,959 |
30 Jun 19 | 14,311 | 3,238 | 2,398 | 1,939 |
31 Mar 19 | 14,351 | 3,116 | 2,351 | 1,859 |
31 Dec 18 | 14,390 | 3,226 | 2,334 | 1,852 |
30 Sep 18 | 14,349 | 3,183 | 2,322 | 1,897 |
30 Jun 18 | 14,271 | 3,194 | 2,308 | 1,837 |
31 Mar 18 | 14,311 | 3,154 | 2,382 | 1,849 |
31 Dec 17 | 14,531 | 3,119 | 2,470 | 1,901 |
30 Sep 17 | 14,572 | 3,131 | 2,486 | 1,895 |
30 Jun 17 | 14,382 | 3,063 | 2,468 | 1,887 |
31 Mar 17 | 14,273 | 3,077 | 2,439 | 1,866 |
31 Dec 16 | 14,142 | 3,050 | 2,414 | 1,865 |
30 Sep 16 | 13,880 | 2,936 | 2,434 | 1,841 |
30 Jun 16 | 14,012 | 2,929 | 2,477 | 1,880 |
31 Mar 16 | 14,032 | 2,861 | 2,464 | 1,931 |
31 Dec 15 | 14,002 | 2,823 | 2,462 | 1,896 |
30 Sep 15 | 13,731 | 2,734 | 2,390 | 1,906 |
30 Jun 15 | 13,393 | 2,630 | 2,342 | 1,878 |
31 Mar 15 | 13,005 | 2,539 | 2,324 | 1,812 |
31 Dec 14 | 12,459 | 2,526 | 2,276 | 1,766 |
30 Sep 14 | 12,218 | 2,484 | 2,338 | 1,688 |
30 Jun 14 | 11,970 | 2,413 | 2,311 | 1,614 |
31 Mar 14 | 11,934 | 2,379 | 2,332 | 1,577 |
31 Dec 13 | 11,746 | 2,200 | 2,321 | 1,528 |
30 Sep 13 | 11,617 | 2,132 | 2,253 | 1,533 |
30 Jun 13 | 11,519 | 2,085 | 2,283 | 1,536 |
Quality Earnings: NSIS N has high quality earnings.
Growing Profit Margin: NSIS N's current net profit margins (16.9%) are lower than last year (20.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NSIS N's earnings have grown by 1.5% per year over the past 5 years.
Accelerating Growth: NSIS N's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: NSIS N had negative earnings growth (-17.7%) over the past year, making it difficult to compare to the Chemicals industry average (-35.1%).
Return on Equity
High ROE: NSIS N's Return on Equity (21.2%) is considered high.